Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 289 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anticoagulation Agents Clear all
Recruiting Phase 4 Interventional

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332
View directory record Official record
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 10:44 AM EDT
Completed No phase listed Observational

Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation

NCT04351438
View directory record Official record
Conditions
Therapeutic Plasma Exchange, Anticoagulant Therapy
Interventions
Active Comparator: centrifuge TPE with citrate, Active Comparator: Filter TPE with heparin, Active comparator: Filter TPE with citrate
Device · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
0 Years to 24 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

NCT00093158
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Acute Disease
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
13,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2007 · Synced Oct 28, 2026, 10:44 AM EDT
Completed No phase listed Observational

Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure

NCT03508271
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
65 Years and older
Enrollment
60,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 28, 2026, 10:44 AM EDT
Withdrawn Not applicable Interventional

Study of Hemostatic Efficacy of the HemCon Dental Dressing in a Population Treated With Anticoagulant Medications

NCT00707564
View directory record Official record
Conditions
Tooth Extractions
Interventions
HemCon Dental Dressing, Gauze with pressure
Device
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Milwaukie, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 28, 2026, 10:44 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

NCT03114566
View directory record Official record
Conditions
Healthy
Interventions
Leukapheresis
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 28, 2026, 10:44 AM EDT
Active, not recruiting Not applicable Interventional

CHAMPION-AF Clinical Trial

NCT04394546
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Ultrasound Guided Platelet Rich Plasma Injections in the Sacroiliac Joint

NCT03122119
View directory record Official record
Conditions
Chronic Low Back Pain, Sacroiliitis, Sacroiliac; Backache, Platelet Rich Plasma, Platelet, Injection Site, Ultrasound Therapy; Complications, Treatment
Interventions
Platelet Rich Plasma Joint Injection
Drug
Lead sponsor
Star Spine and Sport
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI

NCT00093184
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Blue Island, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2006 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

NCT04483583
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 4 Interventional

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

NCT07699796
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Heart, Artery, and Vein Center of Fresno
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF

NCT04907825
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Oral anticoagulant
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

NCT00029315
View directory record Official record
Conditions
Cerebral Hemorrhage
Interventions
Recombinant Tissue Plasminogen Activator (rt-PA)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Not applicable Interventional

Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department

NCT01518335
View directory record Official record
Conditions
Sprain of Ankle
Interventions
Platelet rich plasma injection, Placebo Comparator: Placebo/Standard of Care
Procedure
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 28, 2026, 10:44 AM EDT
Not listed No phase listed Observational

The DARE Warfarin CER Study

NCT03271450
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
416,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 28, 2026, 10:44 AM EDT
Completed No phase listed Observational

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

NCT05264168
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism, DVT
Interventions
Rivaroxaban, Apixaban
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
41,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 28, 2026, 10:44 AM EDT
Not listed No phase listed Observational

Biomarkers of Acute Stroke in Clinic

NCT03897478
View directory record Official record
Conditions
Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions
ISCDX blood test
Diagnostic Test
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 28, 2026, 10:44 AM EDT
Completed No phase listed Observational

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

NCT00788736
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Burlington, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 28, 2026, 10:44 AM EDT
Not listed Not applicable Interventional

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

NCT06232551
View directory record Official record
Conditions
Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
Interventions
EHR (electronic health record) alert, No EHR (electronic health record) alert
Other
Lead sponsor
Scott C. Woller, MD
Other
Eligibility
18 Years to 110 Years
Enrollment
152,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 4 Interventional

Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel

NCT02567461
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Edoxaban 60 mg, Edoxaban 30 mg, Clopidogrel 75 mg, Aspirin 81 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 28, 2026, 10:44 AM EDT
Completed No phase listed Observational

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

NCT05471830
View directory record Official record
Conditions
Prevention of Thromboembolic Events, Atrial Fibrillation
Interventions
Apixaban
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Duration of Therapy for Thrombosis in Children

NCT00687882
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, No Intervention
Other
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
Up to 20 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 28, 2026, 10:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Cytochrome P450 4F Enzymes and Drug Interactions

NCT01250535
View directory record Official record
Conditions
Healthy Volunteers, Drug Drug Interactions
Interventions
Warfarin, Placebo, Lovastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 28, 2026, 10:44 AM EDT